Neurimmune Ag

Neurimmune Ag company information, Employees & Contact Information

Explore related pages

Neurimmune Ag email format Neurimmune Ag management contacts

Related company profiles:

Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, amyotrophic lateral sclerosis, fronto-temporal dementia as well as cardiomyopathy and type 2 diabetes.

Company Details

Employees
62
Founded
-
Address
Wagistrasse 18, Zurich Schlieren,zurich 8952,switzerland
Phone
41 44 755 46 46
Email
in****@****une.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
http://www.neurimmune.com
Keywords
Biotech, human antibodies, Alzheimer's disease, Parkinsons's disease, ALS, cardiomyopathy, type 2 diabetes, drug discovery, drug development, neuroscience, therapeutics.
HQ
Zurich Schlieren, Zurich
Competitors
CDR-Life Inc., Araris Biotech AG, Biognosys, Numab Therapeutics AG, Memo Therapeutics AG, CUTISS AG, NovaGo Therapeutics, ImmunOs Therapeutics AG, Athebio AG, Molecular Partners.
Looking for a particular Neurimmune Ag employee's phone or email?

Neurimmune Ag Questions

News

AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer - PR Newswire

AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer PR Newswire

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease - Yahoo Finance

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease Yahoo Finance

Biogen Sues Ex-Collaborator Over Rights to Drug Tech - USA Herald

Biogen Sues Ex-Collaborator Over Rights to Drug Tech USA Herald

Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab - Biogen

Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab Biogen

Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling - Wiley

Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling Wiley

Biogen quits Aduhelm, handing back rights to original developer - BioPharma Dive

Biogen quits Aduhelm, handing back rights to original developer BioPharma Dive

Neurimmune reports Phase I study results of ATTR-CM drug - Clinical Trials Arena

Neurimmune reports Phase I study results of ATTR-CM drug Clinical Trials Arena

Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006 - PR Newswire

Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006 PR Newswire

Neurimmune, TVM set up ALS biotech, secure support of Eli Lilly unit for advance toward clinical proof of concept - Fierce Biotech

Neurimmune, TVM set up ALS biotech, secure support of Eli Lilly unit for advance toward clinical proof of concept Fierce Biotech

Neurimmune - The Pharma Letter

Neurimmune The Pharma Letter

Meet the Newest ALS Pioneer Company from Switzerland - Labiotech.eu

Meet the Newest ALS Pioneer Company from Switzerland Labiotech.eu

Biogen Walks Away From Aducanumab to Prioritize Lecanemab and Alzheimer Disease Pipeline - NeurologyLive

Biogen Walks Away From Aducanumab to Prioritize Lecanemab and Alzheimer Disease Pipeline NeurologyLive

Neurimmune and Ono Partner to Create New ALS Treatments Based on Antibodies - ALS News Today

Neurimmune and Ono Partner to Create New ALS Treatments Based on Antibodies ALS News Today

Biogen Sues Ex-Collaborator Over Rights To Drug Tech - Law360

Biogen Sues Ex-Collaborator Over Rights To Drug Tech Law360

Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19 - Drug Target Review

Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19 Drug Target Review

Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG - Biogen

Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG Biogen

AstraZeneca adds to rare disease drug pipeline with Neurimmune deal - BioPharma Dive

AstraZeneca adds to rare disease drug pipeline with Neurimmune deal BioPharma Dive

Neurimmune enrols patient in NI006 trial for ATTR cadiomyopathy - Clinical Trials Arena

Neurimmune enrols patient in NI006 trial for ATTR cadiomyopathy Clinical Trials Arena

AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset - Fierce Biotech

AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset Fierce Biotech

Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field - PR Newswire

Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field PR Newswire

Neurimmune’s anti-SOD1 antibody shows promise in ALS mouse studies - Fierce Biotech

Neurimmune’s anti-SOD1 antibody shows promise in ALS mouse studies Fierce Biotech

First ALS Patient Enrolled in Phase 1 Clinical Trial of AP-101 - ALS News Today

First ALS Patient Enrolled in Phase 1 Clinical Trial of AP-101 ALS News Today

Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS - European Medical Journal

Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS European Medical Journal

Just breathe: Ethris, Neurimmune developing inhaled mRNA-encoded COVID-19 antibodies - BioWorld MedTech

Just breathe: Ethris, Neurimmune developing inhaled mRNA-encoded COVID-19 antibodies BioWorld MedTech

Mabimmune AG (merged with Neurimmune) - Venturelab Swiss

Mabimmune AG (merged with Neurimmune) Venturelab Swiss

Neurimmune appoints John Dellapa - European Biotechnology Magazine

Neurimmune appoints John Dellapa European Biotechnology Magazine

Biogen Idec, Neurimmune Report Agreement On 3 Neurodegenerative Disease Programs - RTTNews

Biogen Idec, Neurimmune Report Agreement On 3 Neurodegenerative Disease Programs RTTNews

Neurimmune Appoints Fabian Buller as CBO - European Biotechnology Magazine

Neurimmune Appoints Fabian Buller as CBO European Biotechnology Magazine

Companies like Neurimmune Ag

Araris Biotech AG logo - Similar company to Neurimmune Ag

Araris Biotech Ag

20
ImmunOs Therapeutics AG logo - Similar company to Neurimmune Ag

Immunos Therapeutics Ag

13
NovaGo Therapeutics logo - Similar company to Neurimmune Ag

Novago Therapeutics

10
Molecular Partners logo - Similar company to Neurimmune Ag

Molecular Partners

175
CDR-Life Inc. logo - Similar company to Neurimmune Ag

Cdr-Life Inc.

69
Biognosys logo - Similar company to Neurimmune Ag

Biognosys

91
Memo Therapeutics AG logo - Similar company to Neurimmune Ag

Memo Therapeutics Ag

44
Athebio AG logo - Similar company to Neurimmune Ag

Athebio Ag

24
Numab Therapeutics AG logo - Similar company to Neurimmune Ag

Numab Therapeutics Ag

66
CUTISS AG logo - Similar company to Neurimmune Ag

Cutiss Ag

58

Top Neurimmune Ag Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant